Purdue OxyContin patent ruling
Executive Summary
A New York district court judge rules Jan. 7 that Purdue did not commit inequitable conduct in prosecuting its OxyContin patents before the U.S. Patent and Trademark Office. The court had ruled in 2004 that the patents were invalid and unenforceable due to inequitable conduct in Purdue's infringement suit against Endo. In 2006 the U.S Court of Appeals for the Federal Circuit vacated the district court's finding that the patents on the pain medication were invalid and sent the case back to district court...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.